Myriad Genetics (MYGN)
(Delayed Data from NSDQ)
$27.64 USD
-0.65 (-2.30%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $27.56 -0.08 (-0.29%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth A Momentum A VGM
Earnings News For MYGN
-
Myriad (MYGN) Down 4.8% Since Last Earnings Report: Can It Rebound?
-
Myriad Genetics (MYGN) Q2 Earnings Surpass, '24 Outlook Raised
-
Myriad Genetics (MYGN) Surpasses Q2 Earnings and Revenue Estimates
-
Myriad: Q2 Earnings Snapshot
-
Myriad Genetics Reports Strong Second Quarter 2024 Financial Results, including 15% Revenue Growth Year-Over-Year; Raises 2024 Financial Guidance and Long-Term Revenue Growth Target to 12%
-
Myriad (MYGN) Down 5.2% Since Last Earnings Report: Can It Rebound?
-
Myriad Genetics (MYGN) Posts Narrower-Than-Estimate Loss in Q1
-
Myriad Genetics (MYGN) Reports Q1 Loss, Tops Revenue Estimates
-
Myriad: Q1 Earnings Snapshot
-
Myriad Genetics Reports Strong First Quarter 2024 Financial Results; Achieves 12% Revenue Growth Year-Over-Year; Significantly Improved Year-Over-Year Net Loss and Generated Positive Adjusted EBITDA
-
Will Myriad Genetics (MYGN) Report Negative Q1 Earnings? What You Should Know
-
Why Is Myriad (MYGN) Down 1% Since Last Earnings Report?
-
Myriad Genetics (MYGN) Q4 Earnings Top Estimate, Margins Down
-
Myriad Genetics (MYGN) Tops Q4 Earnings and Revenue Estimates
-
Myriad: Q4 Earnings Snapshot
-
Myriad Genetics Reports Strong Fourth Quarter and Full-Year 2023 Financial Results; Fourth Quarter Revenue of $197 Million and Full-Year Revenue of $753 Million Each Grew 11% Year-Over-Year; Delivered GAAP EPS of $(0.36) and Adjusted EPS of $0.04 in the Fourth Quarter 2023; Raising 2024 Revenue Guidance
-
Why Is Myriad (MYGN) Up 3% Since Last Earnings Report?
-
Myriad Genetics (MYGN) Posts Narrower-Than-Estimate Loss in Q3
-
Myriad: Q3 Earnings Snapshot
-
Myriad Genetics Reports Third Quarter 2023 Financial Results; Generates Double-Digit Revenue Growth; Raises 2023 Revenue Guidance and Introduces 2024 Revenue Guidance
-
Myriad Genetics (MYGN) Posts Narrower-Than-Estimate Q2 Loss
-
Myriad Genetics (MYGN) Reports Q2 Loss, Misses Revenue Estimates
-
Myriad Genetics Reports Second Quarter 2023 Financial Results and Reaffirms 2023 Revenue and Adjusted EPS Guidance; Generates the Fourth Consecutive Quarter of Double-Digit Year-Over-Year Testing Volume Growth
-
Myriad Genetics (MYGN) Lags Q1 Earnings, Updates '23 View
-
Myriad Genetics (MYGN) Reports Q1 Loss, Tops Revenue Estimates